GHK-Cu: what the copper peptide is and how Belle prescribes it
GHK-Cu is a copper peptide your body already makes. Here is what it is, what the research shows, and how Belle prescribes it as a compounded injection.
Guides · Skin · Dr. Pat Taylor, MD · Updated Sep 19, 2026
What GHK-Cu is
GHK-Cu is a copper peptide. The GHK part is a tripeptide, three amino acids (glycine, histidine and lysine) that your body already makes. The Cu is the copper ion it binds. Researchers have found GHK in human plasma, saliva and urine, and its levels decline with age. In the skin, that decline is thought to weaken the signal that tells tissue to rebuild.
GHK-Cu is not an FDA approved drug. It is prescribed off label as a compounded medication by a licensed provider, after a medical intake and your informed consent, and it is prepared for you by a licensed compounding pharmacy. Off label means a licensed provider has judged a use clinically reasonable outside the terms of a brand approval, a common and legal practice in medicine.
Compounded medications are not FDA approved finished products. A licensed provider determines eligibility. That is the pathway, not a warning. It is the reason the provider and the pharmacy matter as much as the molecule.
You have probably met GHK-Cu before, even if the name is new. It has been used in topical skincare for decades and appears widely in products sold on the cosmetic market. Those creams are cosmetics: they sit on the surface of the skin and make no disease claims. Belle offers GHK-Cu as something different, a prescription compounded injection prepared for one patient.
How it is thought to work
GHK is proposed to do its work as a complex with copper, and most of what is known about that work comes from laboratory and animal research. In those studies, researchers have reported that it stimulates the synthesis of collagen, elastin and glycosaminoglycans, the materials that give skin its structure and water content, and supports the function of dermal fibroblasts, the cells that build that structure.
The more interesting finding is that it works in both directions. GHK stimulates both the synthesis and the breakdown of collagen, and it modulates the enzymes that dismantle old tissue as well as their inhibitors. That is remodeling, not simply adding. It is also described as a signal that concentrates activity where repair is needed: in laboratory and animal work it attracts immune and endothelial cells to the site of an injury and stimulates blood vessel and nerve outgrowth.
The gene research is the most striking part. One research group has reported that GHK is capable of up- and downregulating at least 4,000 human genes, and has proposed that this is what explains such a wide range of protective and repair effects from one small molecule. These are described mechanisms under study, not a promise of any result.
What the research shows
Belle draws the same line on its GHK-Cu page that a careful clinician draws in the exam room: what is known, what research suggests, and what is not known yet. Here is the map.
What we know
GHK-Cu is a real, well characterized peptide. It has been studied for decades, and a PubMed search for GHK-Cu returns 180 records as of September 19, 2026. It occurs naturally in the body, and it is widely used in topical skincare products. This is not a molecule that appeared last year.
What research suggests
Research has explored the role of GHK-Cu in collagen, skin remodeling and wound repair. In animal models, researchers reported that it accelerated wound healing of the skin, hair follicles, gastrointestinal tract and bone, and induced wound healing in rats, mice and pigs. The hair follicle findings are the reason it draws interest for hair support, and they are animal data.
In cosmetic products, GHK-Cu has been reported to tighten loose skin and improve elasticity, skin density and firmness, and to reduce fine lines and photodamage. Those are reports from topical use. Much of the strongest evidence to date is topical or from the lab, and it is fair to say so plainly.
What is not known yet
Human data on the injectable route is early. Long term outcomes in people are not established, and individual results vary. Even on the topical side, a 2024 review noted that although GHK-Cu is widely used in anti-wrinkle products, there is a surprising absence of clinical studies using it, and that questions remain about how well it penetrates skin.
That gap is exactly why injectable GHK-Cu is prescribed under supervision rather than sold on a shelf. The remainder of the evidence base is accumulated prescribing experience. That accumulated experience is not nothing. It has shaped clinical intuition in the practitioners who use it, and it is different in kind from a controlled trial. The newest entries in the PubMed record include 2026 primers on injectable peptide therapy written for orthopaedic and sports medicine physicians, a sign that the formal literature is catching up to the clinical use.
Dr. Taylor on GHK-Cu
GHK-Cu is one of the most versatile peptides I prescribe for skin and tissue health. The gene expression research behind it is genuinely interesting: it has been tied to activity across thousands of genes involved in tissue repair. For most patients focused on skin or hair, I set expectations conservatively, because the human data on the injectable route is still catching up, and I monitor and adjust rather than promise a result. Dr. Patrick Taylor, MD, Chief Medical Officer at Belle
Who explores it, and who should wait
Most people who explore GHK-Cu are thinking about skin structure, tone and hair as they get older. In practice, the applications line up with the depth of the research behind them. Skin firmness and texture sit first, because that is where the topical and laboratory record is deepest. Hair support sits next, resting on the hair follicle findings in animal models. Broader tissue repair sits furthest back, with the least human data.
Side effects, as with any compounded injectable, are reviewed with you at intake. The Belle safety information lists injection site reactions and allergic or hypersensitivity reactions for injectable medications as a category. Any new or worsening symptom is worth reporting to your provider promptly, and a serious reaction means seeking medical care right away.
Who should talk to a provider first
- Pregnancy or breastfeeding
- Any GLP-1 or other prescription medication, so everything is reviewed together
- A history of cancer, so your provider can weigh a growth signaling peptide against your history
- Thyroid, kidney or liver disease
- Known allergies or prior reactions to medications or injectables
This is not a list of automatic answers. It is a list of conversations your provider will want to have before prescribing.
How it is taken
Belle prescribes GHK-Cu as a subcutaneous injection you give yourself at home. Route matters here more than it does for many peptides, because the same molecule reaches patients two very different ways. A copper peptide cream is a cosmetic that sits on the skin surface, made the same for everyone, and the published research is still working out how much of it gets past the outer layer. An injection places the peptide under the skin, in a preparation compounded to the prescription your provider wrote for you.
Format is convenience, not medicine. What makes the injection a medical treatment is the review behind it. Dosing is not one-size-fits-all. Your provider sets your dose and schedule after your medical intake, and adjusts it as your protocol progresses.
Belle prescribes GHK-Cu in a 10 week cycle: medication in weeks 1 to 8, then a two week reset that is part of the prescribed protocol, with the pharmacy processing a refill every 10 weeks until you cancel.
Where the real risk is
For most people considering GHK-Cu, the largest risk is not the molecule. It is the vial.
FDA describes compounding as a practice in which a licensed pharmacist or licensed physician combines, mixes or alters the ingredients of a drug to create a medication tailored to the needs of an individual patient. Compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they reach a patient. FDA also notes that compounded drugs can serve an important medical need for certain patients. Read together, that is a description of why the pharmacy and the prescribing provider are the safeguards, not a label.
That is the line that separates a prescription from a research labeled vial. Peptides bought from unverified online vendors, with no prescribing relationship, carry contamination and dosing risks that dwarf any benefit the compound might offer. Those sellers are not pharmacies. If a vial arrives with no prescriber, no pharmacy label and no patient name on it, you are the quality control step.
Belle works only with licensed US compounding pharmacies, and the compounded medications dispensed through Belle are prepared in compliance with applicable state and federal regulations. Your GHK-Cu is made to the prescription your provider wrote, for you, with your name on it.
How Belle prescribes GHK-Cu
It begins with an online intake that takes about five minutes. A licensed provider reviews your health history, your goals and your current medications, then either builds a protocol around you or tells you that GHK-Cu is not the right fit. You are only charged if you are approved and start treatment, shipping is free and tracked, and you can cancel at any time.
A prescription is never guaranteed. If it is not a good fit, the provider will say so rather than prescribe it, and that is the review working as intended. The intake is the information your provider uses to make a decision, so a thorough, honest questionnaire is a good sign, not a hurdle to rush through.
Belle also prescribes BPC-157, MOTS-c and tesamorelin as compounded peptides, each after its own provider review.
Skin turnover is slow, so this is not an overnight change. GHK-Cu is studied for its role in skin remodeling and repair, and remodeling is a gradual process rather than a quick one. Timelines and outcomes vary by individual, and your provider will help you set realistic expectations rather than promise a specific outcome.
Nothing here is medical advice. Decisions about your own care belong with a licensed provider who knows your history.
Key points
- GHK-Cu is a copper peptide found naturally in the body. Its levels decline with age.
- In laboratory and animal research it has been linked to collagen production, skin remodeling and wound repair.
- It is not an FDA approved drug. Belle prescribes it off label as a compounded injection after a medical intake.
- The topical research is decades deep. Human data on the injectable route is still catching up.
- The largest risk is sourcing, not the molecule. A prescription filled by a licensed pharmacy is a different product from a research labeled vial.
Q: Is GHK-Cu FDA approved?
A: No. Compounded GHK-Cu is not FDA approved, and there is no FDA reviewed labeling for it. It is prescribed off label as a compounded medication by a licensed provider, after a medical intake and informed consent, and prepared by a licensed compounding pharmacy for you specifically.
Q: Does Belle offer GHK-Cu?
A: Yes. Belle offers GHK-Cu as a prescription compounded injection, available after an online intake and review by a licensed provider. A prescription is never guaranteed, and you are only charged if you are approved and start treatment.
Q: How is injectable GHK-Cu different from a copper peptide cream?
A: A copper peptide cream is a cosmetic. It is made the same for everyone, sits on the skin surface, and can be bought without any review. Belle GHK-Cu is a prescription treatment: a licensed provider decides whether it fits your history, a licensed compounding pharmacy prepares it to that prescription, and it is given as a subcutaneous injection. The oversight is the difference.
Q: Can I take GHK-Cu alongside my other treatments?
A: Your provider reviews GHK-Cu alongside your current medications and history before prescribing, so everything is considered together. Tell your provider about every treatment you are on, including any GLP-1 medication.
Q: How strong is the human evidence?
A: GHK-Cu is a well characterized peptide with decades of laboratory, animal and topical research behind it. Human data on the injectable route is early, and long term outcomes are not established. The remainder of the evidence base is accumulated prescribing experience, which has shaped how providers use it and is different in kind from a controlled trial.
Q: What kind of results should I expect, and how soon?
A: Skin turnover is slow, so this is not an overnight change. GHK-Cu is studied for its role in skin remodeling and repair, and results vary from person to person. Your provider will help you set realistic expectations rather than promise a specific outcome.
Q: What if it is not right for me?
A: That is what the screening is for. If GHK-Cu is not a good fit, the provider will say so rather than prescribe it, and you are only charged if you are approved and start treatment.
Education only, not medical advice.
